Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041560 | 0.83 | RIPK1 (0.42) | RIPK1LMNAADORA3BRD4ALDH1A1 | |
| SCHEMBL8392778 | 0.81 | SMN1; SMN2 (0.43) | RIPK1LMNAADORA3ALDH1A1RAB9A | |
| SCHEMBL20794010 | 0.79 | RIPK1 (0.52) | RIPK1BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL10041517 | 0.79 | RIPK1 (0.52) | RIPK1BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL10533429 | 0.79 | RIPK1 (0.52) | RIPK1BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL10827450 | 0.74 | LMNA (0.48) | RIPK1LMNAADORA3BRD4ALDH1A1 | |
| SCHEMBL13413567 | 0.74 | TACR1 (0.37) | P2RX7 | |
| SCHEMBL20794007 | 0.73 | ALDH1A1 (0.43) | RIPK1BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL22728678 | 0.73 | ALDH1A1 (0.43) | RIPK1BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL1071984 | 0.69 | P2RX7 (0.50) | RIPK1LMNAADORA3ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | RIPK1 1831/4885LMNA 2932/4885ADORA3 4223/4885 |
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | RIPK1 1831/4885LMNA 2932/4885ADORA3 4223/4885 |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | RIPK1 1831/4885LMNA 2932/4885ADORA3 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.